Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL: NY-ESO-1 157-165 (165V)
DRUG: Nivolumab
BIOLOGICAL: gp100:280-288 (288V)
DRUG: Montanide ISA 51 vegetable grade (VG)
DRUG: Ipilimumab
PROCEDURE: Apheresis Procedure

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]
[object Object]